Key result
Beta-blocker use was not associated with a reduction in the composite endpoint of all-cause death, recurrent MI, or heart failure among post-MI patients with preserved LVEF.
Why the study?
Does routine long-term beta-blocker therapy reduce death, recurrent MI, or heart failure in contemporary post-MI patients with preserved LVEF?
Does routine long-term beta-blocker therapy reduce death, recurrent MI, or heart failure in contemporary post-MI patients with preserved LVEF?
Absolute Event Rate: 8.1% vs 8.3%
Routine long-term beta-blocker therapy does not appear to provide prognostic benefit in contemporary post-MI patients with preserved LVEF, suggesting that treatment should be individualized rather than universally applied.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Galas et al. (2026) conducted an editorial in Prior myocardial infarction with preserved LVEF (n=17,801). Beta-blockers vs. No beta-blockers was evaluated on Composite of all-cause death, recurrent MI, or heart failure. Beta-blocker use was not associated with a reduction in the composite endpoint of all-cause death, recurrent MI, or heart failure among post-MI patients with preserved LVEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: